BioXcel Therapeutics, Inc. is a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. BioXcel's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. BioXcel's two most advanced clinical development programs are BXCL501, an investigational, proprietary, orally dissolving thin film formulation of dexmedetomidine for the treatment of agitation and opioid withdrawal symptoms, and BXCL701, an investigational, orally administered, systemic innate immunity activator in development for the treatment of aggressive forms of prostate cancer and advanced solid tumors that are refractory or treatment naïve to checkpoint inhibitors.
Company profile
Ticker
BTAI
Exchange
Website
CEO
Vimal Mehta
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
BTAI stock data
Analyst ratings and price targets
Current price
Average target
$41.60
Low target
$16.00
High target
$76.00
HC Wainwright & Co.
Maintains
$73.00
Goldman Sachs
Upgraded
$16.00
Mizuho
Maintains
$18.00
Guggenheim
Maintains
$25.00
Canaccord Genuity
Maintains
$76.00
Latest filings (excl ownership)
8-K
Other Events
30 Nov 22
10-Q
2022 Q3
Quarterly report
14 Nov 22
8-K
BioXcel Therapeutics Reports Third Quarter 2022 Financial Results and Recent Operational Highlights
10 Nov 22
8-K
Other Events
12 Sep 22
8-K
Departure of Directors or Certain Officers
19 Aug 22
S-8
Registration of securities for employees
16 Aug 22
10-Q
2022 Q2
Quarterly report
11 Aug 22
8-K
BioXcel Therapeutics Reports Second Quarter 2022 Financial Results and Recent Operational Highlights
9 Aug 22
8-K
Other Events
21 Jul 22
8-K
Other Events
6 Jul 22
Transcripts
BTAI
Earnings call transcript
2022 Q3
10 Nov 22
BTAI
Earnings call transcript
2022 Q2
9 Aug 22
BTAI
Earnings call transcript
2022 Q1
9 May 22
BTAI
Earnings call transcript
2021 Q4
10 Mar 22
BTAI
Earnings call transcript
2021 Q3
10 Nov 21
BTAI
Earnings call transcript
2021 Q2
10 Aug 21
BTAI
Earnings call transcript
2021 Q1
10 May 21
BTAI
Earnings call transcript
2020 Q4
11 Mar 21
BTAI
Earnings call transcript
2020 Q3
12 Nov 20
BTAI
Earnings call transcript
2020 Q2
14 Aug 20
Latest ownership filings
Financial summary
| Quarter (USD) | Sep 22 | Jun 22 | Mar 22 | Dec 21 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 232.31 mm | 232.31 mm | 232.31 mm | 232.31 mm | 232.31 mm | 232.31 mm |
| Cash burn (monthly) | 379.33 k | 1.72 mm | 13.00 mm | 11.07 mm | 10.40 mm | 9.72 mm |
| Cash used (since last report) | 1.48 mm | 6.69 mm | 50.69 mm | 43.19 mm | 40.54 mm | 37.90 mm |
| Cash remaining | 230.83 mm | 225.62 mm | 181.63 mm | 189.13 mm | 191.77 mm | 194.41 mm |
| Runway (months of cash) | 608.5 | 131.4 | 14.0 | 17.1 | 18.4 | 20.0 |
Institutional ownership, Q3 2022
71.1% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 78 |
| Opened positions | 6 |
| Closed positions | 23 |
| Increased positions | 31 |
| Reduced positions | 26 |
| 13F shares | Current |
|---|---|
| Total value | 312.15 mm |
| Total shares | 19.93 mm |
| Total puts | 69.40 k |
| Total calls | 155.40 k |
| Total put/call ratio | 0.4 |
| Largest owners | Shares | Value |
|---|---|---|
| BioXcel | 8.55 mm | $0.00 |
| FMR | 4.20 mm | $49.62 mm |
| BLK Blackrock | 1.46 mm | $17.30 mm |
| Artemis Investment Management | 1.37 mm | $16.26 mm |
| Vanguard | 1.03 mm | $12.18 mm |
| Massachusetts Financial Services | 453.88 k | $5.37 mm |
| Geode Capital Management | 355.53 k | $4.20 mm |
| MS Morgan Stanley | 254.74 k | $3.01 mm |
| Nuveen Asset Management | 217.62 k | $2.57 mm |
| NTRS Northern Trust | 207.87 k | $2.46 mm |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 20 Jan 23 | O'Neill Vincent | Common Stock | Sell | Dispose S | No | Yes | 30 | 29,713 | 891.39 k | 0 |
| 20 Jan 23 | O'Neill Vincent | Common Stock | Option exercise | Acquire M | No | No | 0.41 | 29,713 | 12.18 k | 29,713 |
| 20 Jan 23 | O'Neill Vincent | Employee Stock Option Common Stock | Option exercise | Dispose M | No | No | 0.41 | 29,713 | 12.18 k | 29,712 |
| 20 Jan 23 | Yocca Frank | Common Stock | Sell | Dispose S | No | Yes | 30 | 50,000 | 1.50 mm | 8,397 |
| 5 Jan 23 | Nandabalan Krishnan | Common Stock | Sell | Dispose S | No | Yes | 22.93 | 800 | 18.34 k | 0 |
| 5 Jan 23 | Nandabalan Krishnan | Common Stock | Sell | Dispose S | No | Yes | 22.32 | 25,089 | 559.99 k | 800 |
| 5 Jan 23 | Nandabalan Krishnan | Common Stock | Option exercise | Acquire M | No | No | 0.41 | 25,889 | 10.61 k | 25,889 |
| 5 Jan 23 | Nandabalan Krishnan | Stock Options Common Stock | Option exercise | Dispose M | No | No | 0.41 | 25,889 | 10.61 k | 354,000 |
| 4 Jan 23 | Nandabalan Krishnan | Common Stock | Sell | Dispose S | No | Yes | 22.21 | 9,821 | 218.12 k | 0 |
| 4 Jan 23 | Nandabalan Krishnan | Common Stock | Sell | Dispose S | No | Yes | 21.59 | 24,290 | 524.42 k | 9,821 |
News
Goldman Sachs Maintains Neutral on BioXcel Therapeutics, Raises Price Target to $26
26 Jan 23
HC Wainwright & Co. Maintains Buy on BioXcel Therapeutics, Lowers Price Target to $73
3 Jan 23
BioXcel Therapeutics Announces First Patient Dosed In TRANQUILITY III Phase 3 Trial For Acute Treatment Of Agitation In Patients With Alzheimer's Disease
19 Dec 22
Benzinga's Top Ratings Upgrades, Downgrades For December 1, 2022
1 Dec 22
Analyst Ratings for BioXcel Therapeutics
1 Dec 22
Press releases
BioXcel Therapeutics Announces Promising Top-Line Results from Phase 2 Trial of BXCL701 in Aggressive Form of Rare Prostate Cancer
11 Jan 23
BioXcel Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference
22 Dec 22
BioXcel Therapeutics to Present at Bank of America 2022 Biotech SMID Cap Conference
1 Dec 22
BioXcel Therapeutics Announces First Patients Dosed in SERENITY III Phase 3 Trial for Acute Treatment of Agitation in Adults with Bipolar I or II Disorder or Schizophrenia
30 Nov 22
BioXcel Therapeutics to Present at Two Upcoming Investor Conferences
14 Nov 22